<DOC>
	<DOC>NCT02444286</DOC>
	<brief_summary>To evaluate the safety and efficiency of the MitraClip system in the treatment of patients with clinically significant mitral regurgitation with New York Heart Association (NYHA) Functional Class II to IV chronic heart failure.</brief_summary>
	<brief_title>The RESHAPE-HF1-FU Study</brief_title>
	<detailed_description>The purpose of the RESHAPE-HF1-FU Study is to follow up the safety and effectiveness of the MitraClip System in the treatment of clinically significant Functional Mitral Regurgitation (FMR) in patients with New York Heart Association (NYHA) Functional Class III or IV chronic heart failure, former participants in the RESHAPE-HF Trial (Abbott Vascular).</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Former participant in the RESHAPEHF Trial (Abbott Vascular) Subject agrees to return for all required followup visits The subject has been informed of the nature of the study and agrees to the study's provisions and has provided written informed consent as approved by the respective clinical site's Ethics Committee Withdrawal of Informed Consent Subject belongs to a vulnerable population</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>